Lethal accumulation of procainamide metabolite in severe renal insufficiency.
Four patients, 64-80 years of age, with severe renal dysfunction and heart disease received conventional doses of procainamide as treatment for cardiac arrhythmias. Serum procainamide concentrations at these times ranged from 6.2 to 13.3 micrograms/ml and were within the recently expanded therapeutic range for resistant ventricular arrhythmias. All 4 patients demonstrated marked and delayed accumulation of the active metabolite N-acetylprocainamide, with highest observed serum concentrations ranging from 42.0 to 59.4 micrograms/ml. Cardiotoxicity associated with these levels included progressive widening of the QRS and corrected Q-T intervals, induction of polymorphic non-sustained ventricular tachycardia (torsades de pointes), and severe depression of left ventricular function which appeared to be important factors in the deaths of these patients. The use of lower procainamide doses and careful anticipatory monitoring of serum concentrations of procainamide and N-acetylprocainamide are essential in this high-risk group.
P H
PH
Vlasses
R K
RK
Ferguson
M L
ML
Rocci
R M
RM
Raja
R S
RS
Porter
A M
AM
Greenspan
D000120:Acecainide / Q000378:metabolism*; D000368:Aged; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism*
D000120:Acecainide; D011342:Procainamide